**Linda Genen Joins GeneDx in Senior Clinical Leadership Role**

GeneDx Holdings Corp. (WGS), which specializes in rare disease diagnostics on a global scale, has unveiled a strategic leadership shift by bringing Linda Genen into its executive team. Her appointment centers on driving the company's clinical and medical initiatives forward, with a particular focus on shaping the organization's long-term clinical direction and strategy execution.

Genen brings a robust professional background that spans multiple healthcare sectors. Her career has encompassed direct clinical practice, healthcare economics and insurance frameworks, medical innovation, and specialized expertise in maternal and neonatal health domains. Before joining GeneDx, she held a key position at ProgenyHealth, where she served in a senior clinical capacity and directed the organization's clinical roadmap and medical governance.

In her new capacity at GeneDx, Genen will assume responsibility for the Medical and Clinical Affairs division, positioning her as a driving force behind the company's clinical decision-making and strategic medical planning. Her multifaceted experience in both frontline clinical settings and healthcare administration makes her well-suited to bridge clinical excellence with organizational strategy—a critical function as the rare disease diagnostics sector continues to evolve.

The appointment reflects GeneDx's commitment to strengthening its clinical infrastructure at a time when precision diagnostics are becoming increasingly central to rare disease management. With Genen's track record in building and executing clinical strategies across diverse healthcare environments, the company is positioning itself to enhance its clinical operations and advance its diagnostic capabilities.

*Disclaimer: This represents analysis of the company announcement and does not reflect the views of Nasdaq, Inc.*